Sector News

Bio-Rad Appoints John Goetz as Chief Operating Officer and Announces Other Executive Appointments

October 2, 2014
Life sciences
(Marketwired via COMTEX) – Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostics products, today announced the recent appointment of Mr. John Goetz as Chief Operating Officer. In his new role Mr. Goetz is responsible for all operating functions of the company on a global basis, including the Clinical Diagnostics and Life Science segments as well as global sales.
 
The company also announced that Mr. John Hertia was appointed as Executive Vice President and President of the Clinical Diagnostics Group. Mr. Hertia succeeds Mr. Goetz in leading the company’s worldwide Clinical Diagnostics business. In addition, Ms. Shannon Hall was appointed Executive Vice President and President of the Life Science Group. Prior to this position, Ms. Hall was Vice President and General Manager of the Lab Separations Division in the Life Science Group.
 
Mr. Goetz has been with Bio-Rad for 40 years and has served in various capacities throughout that time including Division Manager of Quality Systems and Group Operations Manager. In 1999, Mr. Goetz led the company’s integration efforts of the newly acquired Pasteur Sanofi Diagnostics business. In 2000, he was appointed to head the Clinical Diagnostics Group.
 
“Mr. Goetz has served the company in many capacities over the years and is well suited to this new position,” said Norman Schwartz, Bio-Rad President and CEO. “We are confident that John has the experience and knowledge needed to move the business forward,” he added.
 
Mr. Hertia began his career with Bio-Rad 32 years ago and has held various positions at the company including Regional Sales Manager, Marketing Manager and later Division Manager of the U.S. Sales Division. He was the Clinical Diagnostics Group’s first Business Development and Strategic Marketing Manager and in 2000, he assumed responsibility of the Clinical Diagnostics Group’s U.S. Operations. In 2006, Mr. Hertia transferred to the company’s Life Science Group as Group Operations Manager. Most recently, Mr. Hertia led the company’s global ERP initiative.
 
Ms. Hall has been with Bio-Rad for 22 years and during that time has held several marketing positions in the Life Science Group beginning with Product Manager and later Business Unit Marketing Manager of the Molecular Biology Business Unit. In 2003, she was named Division Marketing Manager for the Gene Expression Division. In 2007, she transferred to the position of Division Marketing Manager for the Laboratory Separations Division. For the last six years, Ms. Hall led the Lab Separations Division.
 
“We are pleased to have Mr. Hertia lead our Clinical Diagnostics Group as well as Ms. Hall assume the lead of the Life Science Group,” said Mr. Goetz. “Both individuals have broad backgrounds at Bio-Rad and have played active roles in the growth and expansion of the company. We look forward to building on that success.”
 
Source: Bio-Rad Bio-Rad Laboratories, Inc. 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach